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A B S T R A C T
Purpose
Isolated locoregional recurrence (ILRR) predicts a high risk of developing breast cancer distant
metastases and death. The Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR)
trial investigated the effectiveness of chemotherapy (CT) after local therapy for ILRR. A report at
5 years of median follow-up showed signiﬁcant beneﬁt of CT for estrogen receptor (ER)–negative
ILRR, but additional follow-up was required in ER-positive ILRR.
Patients and Methods
CALOR was an open-label, randomized trial for patients with completely excised ILRR after unilateral
breast cancer. Eligible patients were randomly assigned to receive CT or no CT and stratiﬁed by prior CT,
hormone receptor status, and location of ILRR. Patients with hormone receptor–positive ILRR received
adjuvant endocrine therapy. Radiation therapy was mandated for patients with microscopically involved
margins, and anti–human epidermal growth factor receptor 2 therapy was optional. End points were
disease-free survival (DFS), overall survival, and breast cancer-free interval.
Results
From August 2003 to January 2010, 162 patients were enrolled: 58 with ER-negative and 104 with
ER-positive ILRR. At 9 years of median follow-up, 27 DFS events were observed in the ER-negative
group and 40 in the ER-positive group. The hazard ratios (HR) of a DFS event were 0.29 (95%CI, 0.13
to 0.67; 10-year DFS, 70% v 34%, CT v no CT, respectively) in patients with ER-negative ILRR and
1.07 (95%CI, 0.57 to 2.00; 10-year DFS, 50% v 59%, respectively) in patients with ER-positive ILRR
(Pinteraction = .013). HRs were 0.29 (95% CI, 0.13 to 0.67) and 0.94 (95% CI, 0.47 to 1.85), re-
spectively, for breast cancer-free interval (Pinteraction = .034) and 0.48 (95% CI, 0.19 to 1.20) and 0.70
(95% CI, 0.32 to 1.55), respectively, for overall survival (Pinteraction = .53). Results for the three end
points were consistent in multivariable analyses adjusting for location of ILRR, prior CT, and interval
from primary surgery.
Conclusion
The ﬁnal analysis of CALOR conﬁrms that CT beneﬁts patients with resected ER-negative ILRR and
does not support the use of CT for ER-positive ILRR.
J Clin Oncol 36:1073-1079. © 2018 by American Society of Clinical Oncology
INTRODUCTION
The increased use of adjuvant radiation and
systemic therapies and the improved efﬁcacy of
such therapies in the past two decades have
resulted in a lower incidence of locoregional
recurrence of breast cancer.1-5 However, after an
isolated locoregional recurrence (ILRR) event of
breast cancer, the risk of distant metastases
and death is high.6-9 The Chemotherapy as
Adjuvant for LOcally Recurrent breast cancer
(CALOR) trial was designed as a prospective
randomized study to determine the effective-
ness of adjuvant chemotherapy (CT) after surgical
excision of ILRR. Previously, we reported the
results at a median follow-up of 5 years, which
showed signiﬁcant beneﬁt of CT for estrogen
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receptor (ER)–negative ILRR, whereas for patients with ER-
positive ILRR, the beneﬁt of CT was uncertain.10
In a separate analysis, we found that a subset of patients de-
veloped a second ILRR during the ﬁrst 5 years. These events occurred
within a short interval of the ﬁrst ILRR (median, 1.6 years), were
uniquely progesterone-receptor (PR) negative, and were strong in-
dicators of subsequent risk of distant recurrence and death.11 This
report presents results at 9 years of median follow-up, focusing on the
ER-status cohorts, with the aim of further clarifying the effect of CT in
patients with ER-negative and ER-positive ILRR.
PATIENTS AND METHODS
Patients and Procedures
Brieﬂy, CALOR is a pragmatic, open-label, randomized, multicenter
and multinational trial for patients with completely excised ILRR after
unilateral breast cancer.10 Eligible patients were randomly assigned to CT
(selected by the investigator; multidrug for at least 3 months recom-
mended) or no CT and stratiﬁed by prior CT, hormone receptor (ER, PR)
status of ILRR, and location of ILRR. Patients with ER- and/or PR-positive
ILRR were to receive adjuvant endocrine therapy and, if recurrence oc-
curred while receiving endocrine therapy, a regimen change (eg, sub-
stitution of a selective ER modulator with an aromatase inhibitor) was
recommended. Radiation therapy was mandated for patients with mi-
croscopically involved margins and recommended for all patients who had
not received radiotherapy as part of their primary treatment. Human
epidermal growth factor receptor 2 (HER2)–directed therapy was optional.
Follow-up clinical examinations were required every 3 months during the
ﬁrst 2 years, every 6 months during years 3 to 5, and yearly thereafter.
Annual mammography was required, but other laboratory or imaging
studies were left to the discretion of the treating physicians. Participating
institutions’ ethics committees or institutional review boards approved the
trial according to local laws and regulations. All patients gave written
informed consent, and the trial was conducted in compliance with the
Helsinki Declaration. Patient data were anonymized.
International Breast Cancer Study Group (IBCSG) and National
Surgical Adjuvant Breast and Bowel Project/NRG Oncology were re-
sponsible for the design of the study. IBCSG coordinated the collection and
management of the data, medical review, and data analysis. The reporting
of the results was performed jointly.
Outcomes
The primary end point was disease-free survival (DFS), deﬁned as
time from randomization to invasive local, regional, or distant recurrence,
including invasive in-breast tumor recurrence, appearance of a second
primary tumor, or death from any cause. In the absence of an event, DFS
was censored at the date of the last follow-up visit. Overall survival (OS)
and breast cancer–free interval (BCFI)12 were secondary end points. BCFI
was deﬁned as time from randomization to ﬁrst invasive breast tumor
recurrence, with second primary tumors ignored and death from causes
other than breast cancer recurrence censored at the time of death. OS was
deﬁned as the time from randomization to death from any cause.
Statistical Analysis
The present analysis is the ﬁnal update of the results of the CALOR
trial within subgroups deﬁned by the ER status of the ILRR. The subgroup
analysis according to ER status was clinically motivated and prospectively
speciﬁed in the protocol. Because the previously published results at 5 years
Table 1. Patient Characteristics and Treatment Modalities According to ER Status of the ILRR Cohorts
Characteristic
ER Negative ER Positive
Chemotherapy (n = 29) No Chemotherapy (n = 29) Chemotherapy (n = 56) No Chemotherapy (n = 48)
Prior chemotherapy
Yes 17 (59) 21 (72) 32 (57) 31 (65)
No 12 (41) 8 (28) 24 (43) 17 (35)
Location of ILRR
Breast 20 (69) 22 (76) 27 (48) 20 (42)
Mastectomy scar or chest wall 6 (21) 5 (17) 22 (39) 20 (42)
Regional lymph nodes 3 (10) 2 (7) 7 (13) 8 (16)
Primary surgery
Mastectomy 7 (24) 7 (24) 26 (46) 24 (50)
Breast conserving 22 (76) 22 (76) 30 (54) 25 (50)
Time since primary cancer to surgery for ILRR
Median No. of years (range) 3.7 (0.3-21.8) 3.4 (0.4-22.0) 6.1 (0.6-31.6) 8.2 (0.7-20.6)
$ 2 years 23 (79) 22 (75) 49 (88) 43 (90)
Menopausal status at ILRR
Premenopausal 7 (24) 6 (21) 13 (23) 8 (17)
Postmenopausal 22 (76) 23 (79) 43 (77) 40 (83)
Median age at ILRR, years (range) 55 (40-80) 56 (31-82) 56 (37-70) 56 (33-80)
ER of primary tumor
Negative 21 (72) 20 (69) 6 (11) 0 (0)
Positive 7 (24) 8 (28) 42 (75) 39 (81)
Unknown 1 (3) 1 (3) 8 (14) 9 (19)
Treatment of ILRR
Radiation therapy 7 (24) 8 (28) 24 (43) 21 (44)
Endocrine therapy for ER-positive ILRR 53 (92) 50 (98)
Chemotherapy
Monotherapy 9 (31) 16 (29)
Polytherapy 18 (62) 37 (66)
NOTE. Data presented as No. (%) unless otherwise indicated.
Abbreviations: ER, estrogen receptor; ILRR, isolated locoregional recurrence.
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of median follow-up indicated a signiﬁcant interaction between CT effect
and ER status of the ILRR,10 the focus of this update is to provide separate
analyses within ER status cohorts.
We calculated Kaplan-Meier estimates13 of end points at 10 years,
with SEs by Greenwood formula. Cox regression models were used to
estimate HRs (95% CI) for treatment effects within cohorts, to adjust for
the following covariables: location of ILRR, prior chemotherapy, interval
from primary surgery, and ER status of ILRR, and to estimate HRs (95%
CIs) for treatment effects across covariable subgroups by including
treatment-by-covariable interaction in the model; the two-sided P values
for treatment-by-covariable interaction was reported along with the HR
(95% CI) in forest plots.14
The sample size and protocol modiﬁcations have been described
elsewhere. Brieﬂy, the original statistical design was modiﬁed because of
lower-than-planned accrual, and CALOR closed on Jan 31, 2010, with 162
patients enrolled.10 All patients randomly assigned are included in this
intention-to-treat analysis. The database lock was September 2016.
RESULTS
The study cohort consisted of 162 women enrolled from August
2003 to January 2010 (Fig 1). The patient and treatment
characteristics according to ER status are listed in Table 1. The
median time to recurrence from primary cancer to ILRR was 3.6
years for the ER-negative cohort compared with 6.8 years for the
ER-positive cohort; 94% of patients with ER-positive ILRR received
prior endocrine therapy, and only a small proportion of patients
(9%) with ER-positive primary cancers were receiving such
treatment at the time of the ILRR diagnosis.
At 9 years of median follow-up, CT improved DFS sub-
stantially in patients with ER-negative ILRR (Fig 2A): 10-year DFS
was 70% (SE, 9%) in patients with and 34% (SE, 9%) in patients
without CT (hazard ratio [HR] 0.29; 95% CI, 0.13 to 0.67). In
contrast, CT had no beneﬁt in patients with ER-positive ILRR: 10-
year DFS was 50% (SE, 9%) in patients with and 59% (SE, 8%) in
patients without CT (HR, 1.07; 95% CI, 0.57 to 2.00; Fig 2D).
Similarly, BCFI was prolonged by CT in patients with ER-negative
ILRR (breast cancer free at 10 years, 70% v 34%; HR,0.29; 95% CI,
0.13 to 0.67), but not in patients with ER-positive ILRR (58% v
62%; HR, 0.94; 95% CI, 0.47 to 1.85; Figs 2B and 2E). OS at 10
years in patients with ER-negative ILRR was 73% with CT versus
53% without CT (HR, 0.48; 95% CI, 0.19 to 1.20); among patients
with ER-positive ILRR, 10-year OS was 76% versus 66%,
Patients randomly assigned
(N = 162)
With ER-negative ILRR
(n = 58)
Assigned CT (n = 29) (n = 29) (n = 56) (n = 48)
(n = 1)
(n = 47)
(n = 53)
(n = 3)
(n = 0)
(n = 29)
(n = 27)
 (n = 2)
Received CT
Did not receive CT
Analyzed CT (n = 29)
(n = 2)
 (n = 2)
Withdrew consent
Lost to follow-up
Assigned no CT
Received CT
Did not receive CT
(n = 29)
(n = 0)
(n = 2)
Analyzed no CT
Withdrew consent
Lost to follow-up
With ER-positive ILRR
(n = 104)
Assigned CT
Received CT
Did not receive CT
(n = 56)
(n = 5)
(n = 8)
Analyzed CT
Withdrew consent
Lost to follow-up
Assigned no CT
Received CT
Did not receive CT
(n = 48)
(n = 1)
(n = 5)
Analyzed no CT
Withdrew consent
Lost to follow-up
Fig 1. CONSORT diagram of Che-
motherapy as Adjuvant for LOcally Re-
current breast cancer (CALOR) trial
update according to estrogen receptor
(ER) status of the ILRR. CT, chemo-
therapy; ILRR, isolated locoregional re-
currence; LFU, lost to follow-up; no CT,
no chemotherapy.
Table 2. Sites of First Failure (DFS events) After Randomization According to Treatment Group Within ER Status of the ILRR Cohorts
Site
ER Negative, No. (%) ER Positive, No. (%)
CT No CT Total CT No CT Total
Total patients 29 29 58 56 48 104
DFS events 8 (28) 19 (66) 27 (47) 22 (39) 18 (38) 40 (38)
Sites of ﬁrst failure after primary ILRR
Local 1 (3) 4 (14) 5 (9) 3 (5) 3 (6) 6 (6)
Regional 2 (7) 2 (7) 4 (7) 0 1 (2) 1 (1)
Distant 5 (17) 12 (41) 17 (29) 13 (23) 11 (23) 24 (23)
Soft tissue 0 1 (3) 1 (2) 0 1 (2) 1 (1)
Bone 1 (3) 1 (3) 2 (3) 8 (14) 4 (8) 12 (12)
Viscera 4 (14) 10 (34) 14 (24) 5 (9) 6 (13) 11 (11)
Contralateral breast 0 1 (3) 1 (2) 1 (1) 1 (2) 2 (2)
Second (nonbreast) malignancy 0 0 0 3 (5) 1 (2) 4 (4)
Death without prior cancer event 0 0 0 2 (4) 0 2 (2)
Death cause unknown 0 0 0 0 2 (4) 2 (2)
Abbreviations: CT, chemotherapy; DFS, disease-free survival; ER, estrogen receptor; ILRR, isolated locoregional recurrence.
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Fig 2. Disease-free survival (DFS), breast cancer–free interval (BCFI), and overall survival (OS) for patients with (A-C) estrogen-receptor (ER)-negative and (D-F)
ER-positive isolated locoregional recurrence (ILRR). Interaction tests comparing the effect of chemotherapy (CT) for patientswith ER-negative ILRR versus ER-positive ILRR are
Pinteraction = .013 for DFS (A v D); Pinteraction = .034 for BCFI (B v E); and Pinteraction = .53 for OS (C v F). No CT, not assigned to chemotherapy; HR, hazard ratio.
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respectively (HR, 0.70; 95% CI, 0.32 to 1.55; Figs 2C and 2F).
Interaction tests comparing CT effect for ER-positive ILRR versus
ER-negative ILRR are Pinteraction = .013 for DFS (Fig 2A v 2D);
Pinteraction = .034 for BCFI (Fig 2B v 2E); and Pinteraction = .53 for OS
(Fig 2C v Fig 2F). The overall DFS, BCFI, and OS results, not
separated by ER status of the ILRR, are presented in the Data
Supplement.
Overall, there were 67 DFS events, as listed in Table 2. The site
of ﬁrst recurrence after randomization and therefore after the
primary ILRR recurrence was local and regional for 16 patients, six
in the CTarm and 10 in the no-CTarm. Distant disease was the ﬁrst
site of recurrence for 41 patients, 18 patients in the CTarm and 23
patients in the no-CT arm. In the ER-positive cohort, visceral and
bone metastasis rates were similar overall and between treatment
groups. In the ER-negative cohort, bone metastases as site of ﬁrst
recurrence after ILRR were rare (two of 58 patients, one in each
treatment group), whereas visceral metastases were more common
and differed according to treatment group (four of 29 [14%] in the
CT arm; 10 of 29 [34%] no CT arm). All 10 nonbreast cancer DFS
events occurred in the ER-positive cohort; thus, DFS and BCFI
outcomes were the same in the ER-negative cohort (Table 2; Figs
2A and 2B).
The improvement of DFS by CT remained signiﬁcant in
a multivariable proportional hazards model that included factors
for ER status of ILRR, location of ILRR, previous CT use, and
interval from primary surgery. The interaction between ER status
and CT effect was statistically signiﬁcant, conﬁrming the differ-
ential efﬁcacy of CT depending on ER expression of the ILRR
(Table 3). The multivariable analysis of BCFI gave similar results,
again with a statistically signiﬁcant interaction between ER status
and efﬁcacy of CT (data not shown).
The interaction between ER expression and CT effect was
strong and statistically signiﬁcant if the ER status of the ILRR tissue
was considered. In contrast, the ER status of the primary tumor
tissue was less predictive of the efﬁcacy of CT, and the interaction
was not statistically signiﬁcant (Fig 3).
DISCUSSION
The long-term follow-up results of the CALOR trial conﬁrm the
reported ﬁndings of the 5-year analysis10: the statistically signiﬁ-
cant beneﬁt of CT for the cohort of patients with ER-negative ILRR
was sustained. The extended follow-up now available strengthens
conclusions for the ER-positive ILRR cohort: no beneﬁt of CTwas
observed for these patients. Interactions between ER expression of
the ILRR and the use of CT were signiﬁcant for DFS and BCFI.
These results were conﬁrmed in multivariable analyses adjusting
for location of ILRR, prior CT, and interval from primary surgery.
This updated analysis demonstrates that patients with an ILRR
should bemanaged according to the endocrine molecular proﬁle of
the recurrent cancer and not the primary cancer.
The CALOR trial investigated the role of pragmatically chosen
CT, at the discretion of treating physicians. Seemingly, oncologists
selected effective CT regimens for their patients on the basis of
prior cytotoxic agent exposure and in consideration of experienced
toxicities. Although not a trial question, endocrine therapy was
mandated for patients with ER-positive ILRR. In fact, the protocol
recommended a switch of therapy, for example, from a selective ER
modulator to an aromatase inhibitor, especially for the few patients
whose recurrence happened while receiving endocrine treatment.
Because CT did not reduce the number of failures or any of the
measured end points in patients with ER-positive ILRR, it is
reasonable to conclude that endocrine therapy is the mainstay
treatment of such patients.
The strengths of the CALOR trial included its prospective
randomized design and the pragmatic assignment of individual CT
by the participating oncologist. The median follow-up is now
sufﬁciently long to capture the effects of adjuvant CT. The in-
dividualized choice of CT may seem to be a weakness, but the
Table 3. Multivariable Model of Disease-Free Survival
Variable Hazard Ratio (95% CI) P
Location of ILRR
Breast (reference group)
Mastectomy scar or chest wall 0.78 (0.43 to 1.43) .43
Lymph nodes 1.01 (0.47 to 2.16) .98
Prior chemotherapy (yes/no) 0.86 (0.52 to 1.43) .56
Interval from primary surgery (per year) 0.92 (0.87 to 0.97) .0036
Interaction of treatment by ER of ILRR .024
ER negative 0.26 (0.11 to .60)
ER positive 0.87 (0.46 to 1.64)
Abbreviations: ER, estrogen receptor; ILRR, isolated locoregional recurrence.
Events/Total
Chemotherapy No CT Hazard Ratio
Hazard Ratio
(95% CI)
Interaction
P
ER status of ILRR
   Negative
   Positive
ER status of primary tumor
   Negative
   Positive
All patients with known
primary ER status*
28/76
7/28
21/48
9/27
19/49
35/67
18/28
17/39
12/20
23/47
0.62 (0.38 to 1.02)
0.27 (0.11 to 0.64)
1.02 (0.54 to 1.94)
0.75 (0.41 to 1.38)
0.40 (0.17 to 0.95)
.015
.24
Favors
CT
Favors
No CT
.25 1.51.5 2
Disease-Free Survival
Fig 3. Subgroup analysis of disease-free
survival according to estrogen-receptor
(ER) status of isolated locoregional re-
currence (ILRR) and ER status of primary
breast cancer tissue among 143 patients
with known primary ER status. The size of
the boxes is proportional to the number of
events. The x-axis is on a log scale. CT,
assigned to chemotherapy; no CT, not
assigned to chemotherapy. (*) 143 of the
162 randomly assigned patients.
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robust beneﬁt of CT in patients with ER-negative ILRR points to
a generally beneﬁcial effect of CTas chosen by the investigators. In
addition, the availability of ER status for both ILRR and primary
tumor enabled analyses showing that ILRR ER status was the better
predictor of CT beneﬁt. The main weakness of the trial was its
small sample size due to the lower-than-anticipated accrual rate,
which precludes deﬁnitive evaluation of several secondary ques-
tions. For example, given the limited number of ER-positive ILRR
participants and the 12% lost to follow-up rate for this subgroup,
a modest beneﬁt of CT in patients with luminal recurrences could
not be excluded. Furthermore, the beneﬁt of CT in patients with
luminal B-like (eg, ER-positive, PR-negative) recurrences could not
be evaluated. Whereas the interval between primary breast cancer
and ILRR is prognostic, the number of trial participants was in-
sufﬁcient to evaluate whether the time from primary adjuvant CT
to ILRR was predictive of CT beneﬁt after ILRR. In particular,
because of small numbers and a median interval of 3.5 years
between primary diagnosis and ER-negative ILRR, the question of
whether CT effectiveness diminished for short intervals could not
be addressed. The hypothesis of a more pronounced efﬁcacy of CT
in patients who experienced the ER-positive ILRR while receiving
adjuvant endocrine therapy also could not be investigated because
of the low number of patients with these characteristics. Similarly,
although adjuvant taxanes became standard practice during the
accrual period, the inﬂuence of their use before ILRR could not be
evaluated. Furthermore, fewer than 5% of the participants received
HER2-directed adjuvant therapy; thus, this trial cannot shed any
light on the question of HER2-directed therapy for ILRR.
In conclusion, the CALOR trial indicates that at present, CT
offers the best prospect of prolonged DFS in patients with
ER-negative ﬁrst ILRR, whereas adding CT to endocrine therapy
seems to offer no beneﬁt to patients with ER-positive ILRR.
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